Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER plus ) advanced breast cancer (ABC) with progression on endocrine therapy (ET) Meeting Abstract

  

Authors:	Jhaveri, K.; Curigliano, G.; Yap, Y. S.; Cresta, S.; Duhoux, F. P.; Terret, C.; Takahashi, S.; Ulaner, G. A.; Kundamal, N.; Baldoni, D.; Liao, S.; Crystal, A.; Juric, D.
Abstract Title:	Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER plus ) advanced breast cancer (ABC) with progression on endocrine therapy (ET)
Meeting Title:	41st Annual San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	79
Issue:	4 Suppl.
Meeting Dates:	2018 Dec 4-10
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2019-02-01
Language:	English
ACCESSION:	WOS:000478677002385
DOI:	10.1158/1538-7445.Sabcs18-pd1-08
PROVIDER:	wos
Notes:	Meeting Abstract: PD1-08 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/151839